Cargando…

Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis

OBJECTIVES: To systematically review and meta-analyse the evidence for effect modification by refractory status and number of treatment lines in relapsed/refractory multiple myeloma (RRMM); and to assess whether effect modification is likely to invalidate network meta-analyses (NMA) that assume negl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Christopher James, Ohm, Ingrid Kristine, Giske, Liv, Næss, Gunn Eva, Fretheim, Atle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465906/
https://www.ncbi.nlm.nih.gov/pubmed/37643851
http://dx.doi.org/10.1136/bmjopen-2022-067966
_version_ 1785098767890907136
author Rose, Christopher James
Ohm, Ingrid Kristine
Giske, Liv
Næss, Gunn Eva
Fretheim, Atle
author_facet Rose, Christopher James
Ohm, Ingrid Kristine
Giske, Liv
Næss, Gunn Eva
Fretheim, Atle
author_sort Rose, Christopher James
collection PubMed
description OBJECTIVES: To systematically review and meta-analyse the evidence for effect modification by refractory status and number of treatment lines in relapsed/refractory multiple myeloma (RRMM); and to assess whether effect modification is likely to invalidate network meta-analyses (NMA) that assume negligible modification. DESIGN: Systematic review, meta-analysis and simulation. DATA SOURCES: We systematically searched the literature (e.g., OVID Medline) to identify eligible publications in February 2020 and regularly updated the search until January 2022. We also contacted project stakeholders (including industry) ELIGIBILITY CRITERIA: Phase 2 and 3 randomised controlled trials reporting stratified estimates for comparisons with at least one of a prespecified set of treatments relevant for use in Norwegian RRMM patients. OUTCOMES: We used meta-analysis to estimate relative HRs (RHRs) for overall survival (OS) and progression-free survival (PFS) with respect to refractory status and number of treatment lines. We used the estimated RHRs in simulations to estimate the percentage of NMA results expected to differ significantly in the presence versus absence of effect modification. RESULTS: Among the 42 included publications, stratified estimates were published by and extracted from up to 18 (43%) publications and on as many as 8364 patients. Within-study evidence for effect modification is very weak (p>0.05 for 47 of 49 sets of stratified estimates). The largest RHR estimated was 1.32 (95% CI 1.18 to 1.49) for the modifying effect of refractory status on HR for PFS. Simulations suggest that, in the worst case, this would result in only 4.48% (95% CI 4.42% to 4.54%) of NMA estimates differing statistically significantly in the presence versus absence of effect modification. CONCLUSIONS: Based on the available evidence, effect modification appears to be sufficiently small that it can be neglected in adequately performed NMAs. NMAs can probably be relied on to provide estimates of HRs for OS and PFS in RRMM, subject to caveats discussed herein.
format Online
Article
Text
id pubmed-10465906
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-104659062023-08-31 Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis Rose, Christopher James Ohm, Ingrid Kristine Giske, Liv Næss, Gunn Eva Fretheim, Atle BMJ Open Oncology OBJECTIVES: To systematically review and meta-analyse the evidence for effect modification by refractory status and number of treatment lines in relapsed/refractory multiple myeloma (RRMM); and to assess whether effect modification is likely to invalidate network meta-analyses (NMA) that assume negligible modification. DESIGN: Systematic review, meta-analysis and simulation. DATA SOURCES: We systematically searched the literature (e.g., OVID Medline) to identify eligible publications in February 2020 and regularly updated the search until January 2022. We also contacted project stakeholders (including industry) ELIGIBILITY CRITERIA: Phase 2 and 3 randomised controlled trials reporting stratified estimates for comparisons with at least one of a prespecified set of treatments relevant for use in Norwegian RRMM patients. OUTCOMES: We used meta-analysis to estimate relative HRs (RHRs) for overall survival (OS) and progression-free survival (PFS) with respect to refractory status and number of treatment lines. We used the estimated RHRs in simulations to estimate the percentage of NMA results expected to differ significantly in the presence versus absence of effect modification. RESULTS: Among the 42 included publications, stratified estimates were published by and extracted from up to 18 (43%) publications and on as many as 8364 patients. Within-study evidence for effect modification is very weak (p>0.05 for 47 of 49 sets of stratified estimates). The largest RHR estimated was 1.32 (95% CI 1.18 to 1.49) for the modifying effect of refractory status on HR for PFS. Simulations suggest that, in the worst case, this would result in only 4.48% (95% CI 4.42% to 4.54%) of NMA estimates differing statistically significantly in the presence versus absence of effect modification. CONCLUSIONS: Based on the available evidence, effect modification appears to be sufficiently small that it can be neglected in adequately performed NMAs. NMAs can probably be relied on to provide estimates of HRs for OS and PFS in RRMM, subject to caveats discussed herein. BMJ Publishing Group 2023-08-29 /pmc/articles/PMC10465906/ /pubmed/37643851 http://dx.doi.org/10.1136/bmjopen-2022-067966 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Oncology
Rose, Christopher James
Ohm, Ingrid Kristine
Giske, Liv
Næss, Gunn Eva
Fretheim, Atle
Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
title Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
title_full Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
title_fullStr Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
title_full_unstemmed Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
title_short Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
title_sort effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465906/
https://www.ncbi.nlm.nih.gov/pubmed/37643851
http://dx.doi.org/10.1136/bmjopen-2022-067966
work_keys_str_mv AT rosechristopherjames effectmodificationinnetworkmetaanalysesforrelapsedrefractorymultiplemyelomasystematicreviewandmetaanalysis
AT ohmingridkristine effectmodificationinnetworkmetaanalysesforrelapsedrefractorymultiplemyelomasystematicreviewandmetaanalysis
AT giskeliv effectmodificationinnetworkmetaanalysesforrelapsedrefractorymultiplemyelomasystematicreviewandmetaanalysis
AT næssgunneva effectmodificationinnetworkmetaanalysesforrelapsedrefractorymultiplemyelomasystematicreviewandmetaanalysis
AT fretheimatle effectmodificationinnetworkmetaanalysesforrelapsedrefractorymultiplemyelomasystematicreviewandmetaanalysis